This article is more than 5 years old. Information may no longer be current.

Health Canada grants ViaCyte clearance for diabetes clinical trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Health Canada has issued a No Objection Letter to ViaCyte, Inc., giving the company the go-ahead to proceed with sites in Canada for is Phase 1/2 clinical trial of VC-01 product candidate, according to a company press release.

Patients with type 1 diabetes who have minimal to no insulin-producing beta-cell function are being evaluated for the VC-01 product candidate.

“The first cohort of patients in this two-cohort dose escalation study of the VC-01 product candidate is currently being assessed at a single site in the United States,” Paul Laikind, PhD, preside and CEO of ViaCyte, said in a press release. “Should the product candidate proceed to the second cohort, we intend to expand the trial to multiple sites. Health Canada’s approval represents further validation of the trial and allows us to expand internationally to one or more sites in Canada.”

The FDA granted the investigational new drug application for the trial, called STEP ONE, and the study launched in September 2014 at the University of California San Diego Health System.

The trial will evaluate the effectiveness of the product candidate in replacing lost endocrine function. Forty participants are expected to be enrolled in the trial.